

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Docket No. 13115; API-02-06-US)

In the Application of:)
)
Berinstein, et al.)
) Examiner: Anne Marie Sabrina Wehbe
Serial No. 09/693,754)
) Art Unit: 1633
Filing Date: 10/20/2000)
)
Title: Methods of Inducing and / or)
Enhancing an Immune Response)
To Tumor Antigens)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Transmitted via EFS-Web

Supplemental Information Disclosure Statement Under 37 CFR 1.97(c)

Applicants respectfully submit this Supplemental Information Disclosure Statement, PTO-SB08a, and copies of the non-U.S. patent references cited therein. This Information Disclosure Statement is in compliance with the duty of candor as set forth in 37 C.F.R. § 1.56. The Applicant believes no fees are due with this submission; if this is in error, the undersigned hereby authorizes the Commissioner to deduct any required fees from Deposit Account No. 50-0244. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing of the present application.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the references. This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102 or §103.

CITED REFERENCES

U.S. patents and published applications

5,093,258
5,141,742
5,342,774
5,405,940
5,462,871
5,505,941
5,831,016
5,840,839
5,844,075
5,874,560
5,972,597
6,001,349
6,045,802
6,083,703
6,087,110
6,127,116
6,132,980
6,319,496
6,340,462
6,407,063
6,531,451
6,548,068
6,558,671
6,693,086
6,699,475
6,756,038
6,780,407
6,710,172
6,893,869
6,951,917
6,969,609
7,232,887
US 2003/0022854A1
US 2003/0082150A1
US2005/0136066A1
U.S. Ser. No. 09/693,755 filed 10/20/2000

Non-U.S. Patent Documents

WO 96/11279
WO 99/40188
WO 99/46992

Other Documents

COX, et al. Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines. *Science*, vol. 264: 716-719 (1994)

HODGE, et al. Diversified Prime and Boost Protocols Using Recombinant Vaccine Virus and Recombinant Non-Replicating Avian Pox Virus to Enhance T-Cell Immunity and Antitumor Responses. *Vaccine*, vol. 15, issue 6/7, pp. (1997)

HURPIN, et al. The Mode of Presentation and Route of Administration Are Critical for the Induction of Immune Responses to p53 and Antitumor Immunity. *Vaccine*, vol. 16, no. 2/3, pp. 208-215 (1998)

IRVINE, et al. Recombinant Virus Vaccination Against "Self" Antigens Using Anchor-Fixed Immunogens. *Cancer Res.*, vol. 59: 2536-2540 (1999)

KAWAKAMI, et al. Identification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocytes Associated with in vivo Tumor Rejection. *Proc. Natl. Acad. Sci. USA*, vol. 91, pp. 6458-6462 (1994)

KUNDIG, et al. Fibroblasts as Efficient Antigen-Presenting Cells in Lymphoid Organs. *Science*, vol. 268, pp. 1343-1347 (1995)

LEHNER, et al. Targeted Lymph Node Immunization with Simian Immunodeficiency Virus p27 Antigen to Elicit Genital, Rectal, and Urinary Immune Responses in Nonhuman Primates. *J. Immunol.* Vol. 153: 1858-1868 (1994)

LEHNER, et al. Protective Mucosal Immunity Elicited by Targeted Iliac Lymph Node Immunization with a Subunit SIV Envelope and Core Vaccine in Macaques. *Nat. Med.* Vol. 2, No. 7, pp. 767-775 (1996)

LEHNER, et al. The Effect of Route of Immunization on Mucosal Immunity. *J. Infect. Dis.* 179(supp. 3), pp. S489-S492 (1999)

MACKENSEN, et al. Homing of Intravenously and Intralymphatically Injected Human Dendritic Cells Generated in vitro from CD34+ Hematopoietic Progenitor Cells. *Cancer Immunol. Immunother.* Vol. 48, pp. 118-122 (1999)

NESTLE, et al. Vaccination of Melanoma Patients with Peptide- or Tumor Lysate-Pulsed Dendritic Cells. *Nature Med.* Vol. 4, No. 3, pp. 328-332 (1998)

PARKHURST, et al. Improved Induction of Melanoma-Reactive CTL with Peptides from Melanoma Antigen gp100 Modified at HLA-A0201-Binding Residues. *J. Immunol.* Vol. 157, no. 6, pp. 2539-48 (1996)

POND, et al. Interactions Between Adipose Tissue Around Lymph Nodes and Lymphoid Cells in vitro. Vol. 36, pp. 2219-2231 (1995)

PUNT, et al. Biodistribution and Vaccine Efficiency of Murine Dendritic Cells are Dependent on the Route of Administration. Cancer Res. Vol. 59, pp. 3340-3345 (1999)

RAO, et al. Partial Characterization of Two Subpopulations of T4 Cells Induced by Active Specific Intralymphatic Immunotherapy (ASILI) in Melanoma Patients. Vol. 27, abstract 1290 (1986)

RESTIFO, et al. Antigen Processing In Vivo and the Elicitation of Primary CTL Responses. J. Immunol. 154: 4414-4422 (1995)

SALGALLER, et al. Immunization Against Epitopes in the Human Melanoma Antigen gp100 Following Patient Immunization with Synthetic Peptides. Cancer Res. Vol. 56, pp. 4749-4757 (1996)

WIRA, et al. Effect of Uterine Immunization and Oestradiol on Specific IgA and IgG Antibodies in Uterine, Vaginal and Salivary Secretions. Immunology, vol. 68, pp. 24-30 (1989)

WIRA, et al. Specific IgA and IgG Antibodies in the Secretions of the Female Reproductive Tract: Effects of Immunization and Estradiol on Expression of this Response in vitro. J. Immunol. Vol. 138, No. 12, pp. 4159-4164 (1987)

WOLFEL, et al. Two Tyrosine Nonapeptides Recognized on HLA-A2 Melanomas by Autologous Cytolytic T Lymphocytes. Eur. J. Immunol. Vol. 24, pp. 759-764 (1994)

XIANG, et al. An Autologous Oral DNA Vaccine Protects Against Murine Melanoma. Proc. Natl. Acad. Sci. USA, vol. 97, no. 10, pp. 5492-5497 (2000)

ZAREMBA, et al. Identification of an Enhancer Agonist Cytotoxic T Lymphocyte Peptide from Human Carcinoembryonic Antigen. Cancer Res. Vo. 57, pp. 4570-4577 (1997)

Respectfully Submitted,

Date: October 23, 2009

By: /Patrick J. Halloran/
Patrick J. Halloran
Reg. No. 41,053

Patrick J. Halloran, Ph.D., J.D.
3141 Muirfield Road
Center Valley, PA 18034
Tel: 610-984-4751
Fax: 484-214-0164